Identification of Somatic KRAS Mutation in a Korean Baby with Nevus Sebaceus Syndrome

Sung Woo Kim, M.D.1*, Ju Sun Song, M.D.2*, Mi Seon Kang, M.D.3, Jong Beom Sin, M.D.1, Chang-Seok Ki, M.D.2, and Ga Won Jeon, M.D.1

Departments of Pediatrics1 and Pathology3, Busan Paik Hospital, Inje University College of Medicine, Busan; Department of Laboratory Medicine and Genetics2, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Nevus sebaceus is a benign hamartoma of the epidermis, hair follicles, and sebaceous and apocrine glands. It typically appears as a yellow-orange to pink, finely papillomatous alopecic plaque that is often oval or linear. It usually presents at birth, preferentially affects the scalp and face, and is not uncommon, occurring in approximately 1 in 1,000 live births [1].

A recent study by Groesser et al. [1] reported that 95% of patients with nevus sebaceus lesions had somatic mutations in the HRAS gene and 5% had mutations in the KRAS gene, and the HRAS c.37G>C mutation was present in 91% of all lesions as the predominant mutation; approximately 3% of lesions had KRAS c.35G>A (p.Gly12Asp) as the next common mutation. These mutations were not detected in either non-lesional skin tissue or in whole blood, confirming nevus sebaceus as a `mosaic RASopathy’. We report the case of a female infant with nevus sebaceus, in whom a somatic KRAS mutation was identified by Sanger sequencing in a cutaneous lesion.

A 3-day-old female infant was transferred to our institution owing to skin lesions on the scalp, especially over the left parietal and occipital areas. The patient had a slippery, skin-colored, hairless, orange-peel-like linear plaque on her left parietal scalp and face (Fig. 1A) and a round plaque on her occipital scalp (Fig. 1B). Facial examination revealed a limbal dermoid with a skin-colored pedunculated papule on the left eyelid (Fig. 1C). Magnetic resonance imaging of the head showed an arachnoid cyst in the anterior portion of the left temporal lobe, and computed tomographic scanning of the orbit showed a calcified nodular lesion in the medial portion of the left orbit. Echocardiography showed that the patient had an atrial septal defect. A biopsy specimen taken from the plaque showed hyperkeratosis, acanthosis, numerous sebaceous glands, and malformed hair follicles (Fig. 2), consistent with nevus sebaceus.

After obtaining informed consent from the patient’s parents, tissue samples (~5 mm) were collected from a nevus sebaceus lesion of scalp and from normal skin by elective punch biopsy and were subjected to fibroblast culture for expansion. Genomic DNA was extracted from cultured skin fibroblasts as well as from peripheral blood leukocytes using the Wizard Genomic...
DNA Purification Kit (Promega, Madison, WI, USA), following the manufacturer's instructions. Sanger sequencing was performed on DNA extracted from nevus sebaceus tissue, normal skin tissue, and peripheral blood. We initially analyzed the specimens for HRAS c.37G>C (p.Gly13Arg), the most common mutation detected in nevus sebaceus, but were unable to detect this mutation in any of the specimens. Subsequently, we analyzed them for the second most common mutation in nevus sebaceus, KRAS c.35G>A (p.Gly12Asp), and detected this mutation in nevus sebaceus tissue from the patient, but not in her normal skin tissue or peripheral blood, confirming somatic mosaicism (Fig. 3).

RAS proteins regulate cell growth, proliferation, and survival. Mutations in HRAS and KRAS affect mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) signaling pathways, resulting in alterations in cellular growth, proliferation, and differentiation. RAS mutations occur in 30% of human cancers [2] and the most common HRAS c.37G>C and KRAS c.35G>A mutations found in nevus sebaceus are also the most frequent somatic RAS mutations detected in various malignant tumors, according to the catalogue of somatic mutations in cancer (COSMIC) database [1, 3].

Activating RAS mutations have been detected in genomic DNA from nevus sebaceus lesional keratinocytes, but not in DNA derived from adjacent non-lesional skin or peripheral blood, suggesting that cutaneous mosaicism for postzygotic activating mutations in the HRAS and KRAS genes causes nevus sebaceous development. Although germline mutations in these genes have been shown to underlie Costello (OMIM18040) and Noonan syndromes (OMIM163950) [6, 7], these mutations are different from the most common HRAS and KRAS mutations found in nevus sebaceus. It is likely that the common HRAS and KRAS somatic mutations in nevus sebaceus are nonlethal.

Fig. 1. Clinical features of nevus sebaceus. (A) Well-demarcated slippery, skin-colored, orange-peel like, linear plaque on the patient's left parietal scalp and face. (B) Round plaque on the patient's occipital scalp, showing alopecia. (C) A limbal dermoid with a skin-colored pedunculated papule on the left eyelid.

Fig. 2. Pathology of nevus sebaceus showing proliferative changes of sebaceous glands and apocrine glands in the epidermis (H&E, ×100).

Fig. 3. The KRAS mutation (c.35G>A; p.Gly12Asp) was identified in genomic DNA isolated from the nevus sebaceus lesion (arrows), but not from adjacent normal skin tissue or peripheral blood leukocytes.
in a mosaic state but lethal when present in the germline and that they are selected as acquired somatic mutations in human cancers [1].

In approximately 7% of nevus sebaceous patients, the nevus sebaceous lesions may be more extensive with extracutaneous manifestations, and the condition has been defined as nevus sebaceous syndrome [3]. The most frequent extracutaneous manifestation of nevus sebaceous syndrome is central nervous system involvement, and ophthalmologic abnormalities are also common [8]. Our patient had extracutaneous manifestations in the ocular and central nervous system, suggesting the diagnosis of nevus sebaceous syndrome. According to the studies by Groesser et al. [1] and Sun et al. [9], extensive mosaicism for activating HRAS and KRAS mutations involving the skin, skeletal, ocular and central nervous systems is considered to be the underlying genetic cause of nevus sebaceous syndrome.

In conclusion, although nevus sebaceous and nevus sebaceous syndrome are relatively common skin disorders, there has been no prior report on a genetically confirmed case in Korea. In this study, we present the first case of a female infant who had nevus sebaceous accompanied by extracutaneous manifestations, suggesting the diagnosis of nevus sebaceous syndrome, and in whom a somatic KRAS mutation (c.35G>A; p.Gly12Asp) was identified in the cutaneous lesion. Close monitoring for the potential development of secondary tumors is advised for this patient.

Authors’ Disclosures of Potential Conflicts of Interest

No potential conflicts of interest to this article were reported.

REFERENCES

1. Groesser L, Herschberger E, Ruetten A, Ruivenkamp C, Lopriore E, Zutt M, et al. Postzygotic HRAS and KRAS mutations cause nevus sebaceous and Schimmelpenning syndrome. Nat Genet 2012;44:783-7.
2. Shaw RJ and Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006;441:424-30.
3. Aslam A, Salam A, Griffiths CE, McGrath JA. Naevus sebaceus: a mosaic RASopathy. Clin Exp Dermatol 2014;39:1-6.
4. Levisohn JL, Tian LC, Boyden LM, McNiff JM, Narayan D, Loring ES, et al. Whole-exome sequencing reveals somatic mutations in HRAS and KRAS, which cause nevus sebaceous. J Invest Dermatol 2013;133:827-30.
5. Happle R. Nevus sebaceous is a mosaic RASopathy. J Invest Dermatol 2013;133:597-600.
6. Schubbert S, Zenker M, Rowe SL, Böll S, Klein C, Bollag G, et al. Germ-line KRAS mutations cause Noonan syndrome. Nat Genet 2006;38:331-6.
7. Aoki Y, Niihori T, Kawame H, Kurosawa K, Ohashi H, Tanaka Y, et al. Germline mutations in HRAS proto-oncogene cause Costello syndrome. Nat Genet 2005;37:1038-40.
8. Brandling-Bennett HA Morel KD. Epidermal nevi. Pediatr Clin North Am 2010;57:1177-98.
9. Sun BK, Saggini A, Sarin KY, Kim J, Benjamin L, LeBoit PE, et al. Mosaic activating RAS mutations in nevus sebaceous and nevus sebaceous syndrome. J Invest Dermatol 2013;133:824-7.